Oramed Announces $6.5 Million Milestone Payment from HTIT

Payment comes in wake of positive topline phase IIB results

JERUSALEM, June 21, 2016 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced that Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT) is transferring a $6.5 million milestone […]

Categories: 新闻通稿|Tags: |

Oramed to Present at the American Diabetes Association 76th Scientific Sessions

JERUSALEM, June 9, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing a study performed in animals with its orally ingestible insulin capsule, ORMD-0801, will be presented […]

Categories: 新闻通稿|Tags: |

Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study

All Primary Safety and Efficacy Endpoints Were Met; Conference Call Today at 11:00 am EDT

JERUSALEM, May 18, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), today announced positive top-line results from its Phase IIb study, designed to evaluate the safety and efficacy of its oral insulin […]

Categories: 新闻通稿|Tags: |

Oramed to Present at Oppenheimer Annual Israeli Conference

JERUSALEM, May 16, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Oppenheimer Annual Israeli Conference, taking place on May 22, 2016 in […]

Categories: 新闻通稿|Tags: |

Oramed Patent Being Granted in China for Oral Administration of Proteins

JERUSALEM, May 11, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a developer of oral drug delivery systems, announced today that an official Notification of Granting Patent Right was issued for the Company’s patent for its invention titled “Methods and Compositions for Oral Administrations of […]

Categories: 新闻通稿|Tags: |

Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar

JERUSALEM, April 28, 2016
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar & Co. LLC, taking place on […]

Categories: 新闻通稿|Tags: |

Oramed Receives Patent Term Adjustment Extending the Term of Its U.S. Patent

Patent addresses platform technology for oral insulin capsule ORMD-0801

JERUSALEM, April 12, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Patent and Trademark Office (PTO) has issued a […]

Categories: 新闻通稿|Tags: |

Oramed Completes Phase IIb Oral Insulin Study

Top-Line Data to be Released This Quarter

JERUSALEM, April 5, 2016
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that all follow-up visits in the Company’s Phase IIb study of its oral insulin capsule, […]

Categories: 新闻通稿|Tags: |

Oramed Patent Granted in India for Oral Administration of Proteins

JERUSALEM, March 29, 2016
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a developer of oral drug delivery systems, announced today that the Company’s patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office.
About Oramed Pharmaceuticals

Oramed Pharmaceuticals […]

Categories: 新闻通稿|Tags: |

Oramed to Present at the BIO CEO & Investor Conference

JERUSALEM, February 4, 2016
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://chinese.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 18th Annual BIO CEO & Investor Conference, taking place February 8-9, 2016 in […]

Categories: 新闻通稿|Tags: |